No Data
No Data
Analysts Conflicted on These Healthcare Names: Humana (HUM) and Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals Showcases PTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Express News | Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
H.C. Wainwright Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
H.C. Wainwright Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Cuts Target Price to $11
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Cuts Target Price to $10